Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from RAPT Therapeutics ( (RAPT) ).
On May 29, 2025, RAPT Therapeutics‘ stockholders approved a 1-for-8 reverse stock split of the company’s common stock, which was executed on June 16, 2025. This corporate action reduced the number of outstanding shares to approximately 16.5 million, potentially impacting the company’s stock market performance and shareholder value.
The most recent analyst rating on (RAPT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.
Spark’s Take on RAPT Stock
According to Spark, TipRanks’ AI Analyst, RAPT is a Underperform.
RAPT Therapeutics’ overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.
To see Spark’s full report on RAPT stock, click here.
More about RAPT Therapeutics
RAPT Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
Average Trading Volume: 945,352
Technical Sentiment Signal: Sell
Current Market Cap: $136.3M
For a thorough assessment of RAPT stock, go to TipRanks’ Stock Analysis page.